Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22

Despite high remission rates following CAR-T cell therapy in B-ALL, relapse due to loss of the targeted antigen is increasingly recognized as a mechanism of immune escape. We hypothesized that simultaneous targeting of CD19 and CD22 may reduce the likelihood of antigen loss, thus improving sustained...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Mol Ther Oncolytics
Prif Awduron: Qin, Haiying, Ramakrishna, Sneha, Nguyen, Sang, Fountaine, Thomas J., Ponduri, Anusha, Stetler-Stevenson, Maryalice, Yuan, Constance M., Haso, Waleed, Shern, Jack F., Shah, Nirali N., Fry, Terry J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Gene & Cell Therapy 2018
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6300726/
https://ncbi.nlm.nih.gov/pubmed/30581986
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omto.2018.10.006
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg